Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
19 Leser
Artikel bewerten:
(0)

FDA Warning: Consumers Advised Not to Use Arrow Brand Medicated Oil & - Embrocation or Aceite Medicinal La Flecha / 'Medicated' oil claiming to treat multitude of ailments is potentially toxic

SILVER SPRING, Md., May 27 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned consumers not to purchase or use a product called "Arrow Brand Medicated Oil & Embrocation," also labeled as "Aceite Medicinal La Flecha" (Spanish) or Mandarin. The product is potentially toxic and contains two substances, methyl salicylate and camphor, which are poisonous when ingested.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Methyl salicylate and camphor also may be poisonous when applied to a large area of the skin, or when combined with heat to increase absorption of the active ingredients. Children are particularly susceptible to poisoning from these ingredients.

Symptoms of poisoning from these ingredients could include: abdominal pain, nausea, vomiting, diarrhea, headache, visual changes, dizziness and mental confusion. Some cases of accidental overdose of methyl salicylate and camphor have been fatal.

FDA preliminary testing on product samples also revealed a compound that appears to be diethylene glycol (DEG), an ingredient used in antifreeze, which may be toxic if ingested. Further testing is needed to confirm the presence of DEG.

The product is sold primarily on the Internet and in specialty stores that serve Asian and Latino communities. The FDA is asking retailers to remove the product from store shelves.

For more information FDA Questions and Answers for the Public in English

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm213 484.htm

Questions and Answers in Spanish

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm213 661.htm

Questions and Answers in Mandarin

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm213 662.htm

Media Inquiries: Elaine Gansz Bobo, 301-796-7567, elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

Photo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO
PRN Photo Desk, photodesk@prnewswire.com

U.S. Food and Drug Administration

CONTACT: Elaine Gansz Bobo of the U.S. Food and Drug Administration,
+1-301-796-7567, elaine.bobo@fda.hhs.gov

Web Site: http://www.fda.gov/

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.